This week, the company formerly known as MAPS PBC—Lykos Therapeutics—announced that the FDA will start the review process for MDMA-Assisted Therapy in June.
Excellent summary! Thank you Zach for a clear, readable outline on the state of insurance counter-health financial incentives and access to much needed psychedelic-assisted therapies. How should we advocate for these life-saving therapies on a local, regional, and national level?
Excellent summary! Thank you Zach for a clear, readable outline on the state of insurance counter-health financial incentives and access to much needed psychedelic-assisted therapies. How should we advocate for these life-saving therapies on a local, regional, and national level?